Rothschild Investment Corp IL Invests $201,000 in Urogen Pharma Ltd (URGN)

Rothschild Investment Corp IL purchased a new position in Urogen Pharma Ltd (NASDAQ:URGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,250 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Northern Trust Corp acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $677,000. Jane Street Group LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $227,000. California Public Employees Retirement System acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $840,000. Millennium Management LLC lifted its position in shares of Urogen Pharma by 8.3% during the 2nd quarter. Millennium Management LLC now owns 172,332 shares of the company’s stock valued at $8,575,000 after acquiring an additional 13,219 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter valued at $333,000. Hedge funds and other institutional investors own 71.11% of the company’s stock.

Urogen Pharma stock opened at $42.26 on Friday. Urogen Pharma Ltd has a 12-month low of $25.56 and a 12-month high of $69.57.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, August 14th. The company reported ($1.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.25). Urogen Pharma had a negative return on equity of 44.24% and a negative net margin of 470.54%. The business had revenue of $0.36 million for the quarter. Analysts forecast that Urogen Pharma Ltd will post -4.12 earnings per share for the current year.

A number of research analysts recently issued reports on URGN shares. Stifel Nicolaus started coverage on shares of Urogen Pharma in a research report on Thursday, September 13th. They set a “buy” rating and a $70.00 target price on the stock. Oppenheimer set a $75.00 target price on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Tuesday, August 14th. Cowen reiterated a “buy” rating on shares of Urogen Pharma in a research report on Tuesday, August 14th. Finally, Zacks Investment Research downgraded shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $65.25.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Recommended Story: Why is insider trading harmful?

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply